Literature DB >> 34857884

A tale of two antiviral targets - and the COVID-19 drugs that bind them.

Megan Cully.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 34857884     DOI： 10.1038/d41573-021-00202-8

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  39 in total

Review 1.  An insight into SARS-CoV-2 structure, pathogenesis, target hunting for drug development and vaccine initiatives.

Authors:  Arijit Ghosh; Paritosh K Kar; Anupam Gautam; Rahul Gupta; Rajveer Singh; Rudra Chakravarti; Velayutham Ravichandiran; Shubhra Ghosh Dastidar; Dipanjan Ghosh; Syamal Roy
Journal:  RSC Med Chem       Date:  2022-01-25

Review 2.  Advances and applications of monoolein as a novel nanomaterial in mitigating chronic lung diseases.

Authors:  Yinghan Chan; Sachin Kumar Singh; Monica Gulati; Sheetu Wadhwa; Parteek Prasher; Deepak Kumar; Avvaru Praveen Kumar; Gaurav Gupta; Gowthamarajan Kuppusamy; Mehra Haghi; Brian Gregory George Oliver; Jon Adams; Dinesh Kumar Chellappan; Kamal Dua
Journal:  J Drug Deliv Sci Technol       Date:  2022-06-23       Impact factor: 5.062

Review 3.  The Immune System of Marine Organisms as Source for Drugs against Infectious Diseases.

Authors:  Alberto Falco; Mikolaj Adamek; Patricia Pereiro; David Hoole; José Antonio Encinar; Beatriz Novoa; Ricardo Mallavia
Journal:  Mar Drugs       Date:  2022-05-28       Impact factor: 6.085

4.  Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance.

Authors:  Ala M Shaqra; Sarah N Zvornicanin; Qiu Yu J Huang; Gordon J Lockbaum; Mark Knapp; Laura Tandeske; David T Bakan; Julia Flynn; Daniel N A Bolon; Stephanie Moquin; Dustin Dovala; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  Nat Commun       Date:  2022-06-21       Impact factor: 17.694

5.  Post-acute Sequelae of SARS-CoV-2 Infection: A Neglected Public Health Issue.

Authors:  Zhonglei Wang; Liyan Yang
Journal:  Front Public Health       Date:  2022-06-17

6.  In Vitro Evaluation and Mitigation of Niclosamide's Liabilities as a COVID-19 Treatment.

Authors:  Jesse W Wotring; Sean M McCarty; Khadija Shafiq; Charles J Zhang; Theophilus Nguyen; Sophia R Meyer; Reid Fursmidt; Carmen Mirabelli; Martin C Clasby; Christiane E Wobus; Matthew J O'Meara; Jonathan Z Sexton
Journal:  bioRxiv       Date:  2022-07-13

7.  Development of a colorimetric assay for the detection of SARS-CoV-2 3CLpro activity.

Authors:  Gavin D Garland; Robert F Harvey; Thomas E Mulroney; Mie Monti; Stewart Fuller; Richard Haigh; Pehuén Pereyra Gerber; Michael R Barer; Nicholas J Matheson; Anne E Willis
Journal:  Biochem J       Date:  2022-04-29       Impact factor: 3.766

Review 8.  Omicron: Understanding the Latest Variant of SARS-CoV-2 and Strategies for Tackling the Infection.

Authors:  Sreekanth Reddy Obireddy; Ujwala Guntakanti; Anitha Kowthalam; Subha Marata Chinna Subbarao; Wing-Fu Lai
Journal:  Chembiochem       Date:  2022-04-19       Impact factor: 3.461

Review 9.  Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.

Authors:  Paul Andrei Negru; Andrei-Flavius Radu; Cosmin Mihai Vesa; Tapan Behl; Mohamed M Abdel-Daim; Aurelia Cristina Nechifor; Laura Endres; Manuela Stoicescu; Bianca Pasca; Delia Mirela Tit; Simona Gabriela Bungau
Journal:  Biomed Pharmacother       Date:  2022-02-04       Impact factor: 6.529

10.  Computational Analysis of Molnupiravir.

Authors:  Artem V Sharov; Tatyana M Burkhanova; Tugba Taskın Tok; Maria G Babashkina; Damir A Safin
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.